1. Home
  2. CNTA vs MTRN Comparison

CNTA vs MTRN Comparison

Compare CNTA & MTRN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CNTA
  • MTRN
  • Stock Information
  • Founded
  • CNTA 2020
  • MTRN 1931
  • Country
  • CNTA United Kingdom
  • MTRN United States
  • Employees
  • CNTA N/A
  • MTRN N/A
  • Industry
  • CNTA Biotechnology: Pharmaceutical Preparations
  • MTRN Industrial Specialties
  • Sector
  • CNTA Health Care
  • MTRN Industrials
  • Exchange
  • CNTA Nasdaq
  • MTRN Nasdaq
  • Market Cap
  • CNTA 2.3B
  • MTRN 2.3B
  • IPO Year
  • CNTA 2021
  • MTRN N/A
  • Fundamental
  • Price
  • CNTA $16.64
  • MTRN $110.86
  • Analyst Decision
  • CNTA Strong Buy
  • MTRN Strong Buy
  • Analyst Count
  • CNTA 10
  • MTRN 2
  • Target Price
  • CNTA $30.56
  • MTRN $123.50
  • AVG Volume (30 Days)
  • CNTA 1.0M
  • MTRN 168.0K
  • Earning Date
  • CNTA 08-12-2025
  • MTRN 10-29-2025
  • Dividend Yield
  • CNTA N/A
  • MTRN 0.51%
  • EPS Growth
  • CNTA N/A
  • MTRN N/A
  • EPS
  • CNTA N/A
  • MTRN 0.78
  • Revenue
  • CNTA $15,000,000.00
  • MTRN $1,725,574,000.00
  • Revenue This Year
  • CNTA N/A
  • MTRN $5.95
  • Revenue Next Year
  • CNTA N/A
  • MTRN $6.78
  • P/E Ratio
  • CNTA N/A
  • MTRN $142.93
  • Revenue Growth
  • CNTA 118.88
  • MTRN 5.52
  • 52 Week Low
  • CNTA $9.60
  • MTRN $69.10
  • 52 Week High
  • CNTA $19.09
  • MTRN $123.21
  • Technical
  • Relative Strength Index (RSI)
  • CNTA 49.69
  • MTRN 62.30
  • Support Level
  • CNTA $16.27
  • MTRN $108.87
  • Resistance Level
  • CNTA $16.84
  • MTRN $114.10
  • Average True Range (ATR)
  • CNTA 0.70
  • MTRN 2.95
  • MACD
  • CNTA -0.21
  • MTRN -0.92
  • Stochastic Oscillator
  • CNTA 16.93
  • MTRN 60.94

About CNTA Centessa Pharmaceuticals plc

Centessa Pharmaceuticals PLC is a clinical-stage pharmaceutical company. The company's pipeline assets include: SerpinPC for Hemophilia A, B; LB101 for Solid Tumors; ORX750 for Narcolepsy Type 1 (NT1) and other sleep disorders; MGX292 Pulmonary Arterial Hypertension (PAH); and Undisclosed for Solid Tumors.

About MTRN Materion Corporation

Materion Corp specializes in the development of specialty engineered alloy systems, inorganic chemicals and powders, precious and non-precious metals, beryllium and beryllium composites, and precision filters and optical coatings. The company operates in four reportable segments: Performance Materials, Electronic Materials, Precision Optics, and Others. The majority of revenue is derived from Electronic Materials which produces chemicals, microelectronics packaging, precious metal, non-precious metal, and specialty metal products, including vapor deposition targets, frame lid assemblies, clad and precious metal pre-forms. The Performance Materials segment provides engineered solutions comprised of beryllium and non-beryllium-containing alloy systems and custom-engineered parts.

Share on Social Networks: